A Phase 3 interventional study of Synflorix and Infanrix hexa in Infections, Streptococcal and Streptococcus Pneumoniae Vaccines, sponsored by GlaxoSmithKline. Completed at 2 sites in Mexico. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-13.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing PHiD-CV vaccine in Streptococcal Infections — none open to participants now, none under way, none of them phase 3. PHiD-CV vaccine · Streptococcal Infections.
Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, this one is the 21st largest by enrollment, is one of 4 that started in 2007, is one of 24 in phase 3, and was the 3rd registered.
147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.
Browse Streptococcal Infections studies →None of the 25 studies testing PHiD-CV vaccine in Streptococcal Infections is open now. The open studies under Streptococcal Infections, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is below the median of 270 across 106 interventional studies indexed under Streptococcal Infections.
Median enrollment 360 across the 25 interventional studies. Of the 25 that completed or were terminated, 25 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 25 have an industry lead sponsor. The 1 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
64 studies in Streptococcal Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 61 finished, 44 (72%) have results posted.
Among the 64 studies in Streptococcal Infections by GlaxoSmithKline, this one is the 41st largest by enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2007, is one of 38 in phase 3, and was the 14th registered.
GlaxoSmithKline’s Streptococcal Infections studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 64 in Streptococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of Mexican infants with pneumococcal conjugate vaccine GSK 1024850A co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined vaccine (Infanrix hexa) and rotavirus vaccine (Rotarix) in children during the first 6 months of age.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
Biological: Synflorix · Biological: Infanrix hexa · Biological: Rotarix
Intramuscular injection, 3 doses.
Also known as: Pneumococcal conjugate vaccine GSK1024850A.
Intramuscular injection, 3 doses.
Oral, 2 doses.
Antibody Concentrations Against Pneumococcal Vaccine Serotypes
Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Antibody Concentrations Against Protein D
Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes
The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes
Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes
The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes
Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes
Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes
Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes
Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Number of Subjects Seropositive for Anti-Protein D Antibodies
Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.
Time frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Grade 3 redness and swelling was \> 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of grade and whatever the number of injections.
Time frame: Within 4 days following any vaccine dose
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature \> 39.5°C. Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities. Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day. Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.
Time frame: Within 4 days following any vaccine dose
Number of Subjects Reporting Any Unsolicited AEs
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: Within 31 days after any vaccine dose
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: Up to Month 5
| Milestone | Synflorix Vaccine Group |
|---|---|
| Started | 230 |
| Completed | 226 |
| Not completed | 4 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 1 |
Concentrations were expressed as geometric mean concentration (GMC). The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
| microgram per milliliter | Synflorix Vaccine Group |
|---|---|
| Anti-1 antibody (N=219) | 2.13 (1.94 to 2.34) |
| Anti-4 antibody (N=218) | 3.04 (2.77 to 3.34) |
| Anti-5 antibody (N=218) | 3.24 (2.97 to 3.53) |
| Anti-6B antibody (N=218) | 1.32 (1.14 to 1.54) |
| Anti-7F antibody (N=218) | 3.72 (3.40 to 4.07) |
| Anti-9V antibody (N=218) | 3.71 (3.37 to 4.09) |
| Anti-14 antibody (N=218) | 5.27 (4.66 to 5.96) |
| Anti-18C antibody (N=219) | 6.05 (5.30 to 6.89) |
| Anti-19F antibody (N=219) | 5.49 (4.88 to 6.17) |
| Anti-23F antibody (N=218) | 2.00 (1.70 to 2.35) |
Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.
| ELISA units per milliliter | Synflorix Vaccine Group |
|---|---|
| Antibody Concentrations Against Protein D | 2923.2 (2588.6 to 3301.1) |
The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
| titer | Synflorix Vaccine Group |
|---|---|
| Opsono-1 titer (N=97) | 94.1 (68.2 to 130.0) |
| Opsono-4 titer (N=97) | 670.8 (516.1 to 871.7) |
| Opsono-5 titer (N=94) | 148.8 (120.6 to 183.6) |
| Opsono-6B titer (N=96) | 345.4 (205.5 to 580.4) |
| Opsono-7F titer (N=96) | 4435.4 (3635.9 to 5410.7) |
| Opsono-9V titer (N=96) | 1186.1 (955.9 to 1471.7) |
| Opsono-14 titer (N=94) | 1168.3 (907.4 to 1504.2) |
| Opsono-18C titer (N=94) | 222.9 (157.9 to 314.9) |
| Opsono-19F titer (N=92) | 589.2 (441.9 to 785.5) |
| Opsono-23F titer (N=95) | 1876.3 (1325.4 to 2656.0) |
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
| subjects | Synflorix Vaccine Group |
|---|---|
| Anti-1 antibody (N=219) | 219 |
| Anti-4 antibody (N=218) | 218 |
| Anti-5 antibody (N=218) | 218 |
| Anti-6B antibody (N=218) | 203 |
| Anti-7F antibody (N=218) | 218 |
| Anti-9V antibody (N=218) | 218 |
| Anti-14 antibody (N=218) | 216 |
| Anti-18C antibody (N=219) | 218 |
| Anti-19F antibody (N=219) | 217 |
| Anti-23F antibody (N=218) | 207 |
Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.
| microgram per milliliter | Synflorix Vaccine Group |
|---|---|
| Anti-6A antibody | 0.28 (0.24 to 0.34) |
| Anti-19A antibody | 0.26 (0.22 to 0.31) |
The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
| titer | Synflorix Vaccine Group |
|---|---|
| Opsono-6A titer (N=91) | 159.2 (98.8 to 256.4) |
| Opsono-19A titer (N=81) | 11.6 (7.3 to 18.4) |
Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
| subjects | Synflorix Vaccine Group |
|---|---|
| Anti-1 antibody (N=219) | 219 |
| Anti-4 antibody (N=218) | 218 |
| Anti-5 antibody (N=218) | 218 |
| Anti-6B antibody (N=218) | 212 |
| Anti-7F antibody (N=218) | 218 |
| Anti-9V antibody (N=218) | 218 |
| Anti-14 antibody (N=218) | 218 |
| Anti-18C antibody (N=219) | 218 |
| Anti-19F antibody (N=219) | 219 |
| Anti-23F antibody (N=218) | 212 |
Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
| subjects | Synflorix Vaccine Group |
|---|---|
| Opsono-1 titer (N=97) | 83 |
| Opsono-4 titer (N=97) | 93 |
| Opsono-5 titer (N=94) | 93 |
| Opsono-6B titer (N=96) | 76 |
| Opsono-7F titer (N=96) | 96 |
| Opsono-9V titer (N=96) | 96 |
| Opsono-14 titer (N=94) | 93 |
| Opsono-18C titer (N=94) | 91 |
| Opsono-19F titer (N=92) | 90 |
| Opsono-23F titer (N=95) | 90 |
Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter. The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
| subjects | Synflorix Vaccine Group |
|---|---|
| Anti-6A antibody | 203 |
| Anti-19A antibody | 198 |
Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.
| subjects | Synflorix Vaccine Group |
|---|---|
| Opsono-6A titer (N=91) | 69 |
| Opsono-19A titer (N=81) | 19 |
Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.
| subjects | Synflorix Vaccine Group |
|---|---|
| Number of Subjects Seropositive for Anti-Protein D Antibodies | 219 |
Grade 3 redness and swelling was \> 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of grade and whatever the number of injections.
| subjects | Synflorix Vaccine Group |
|---|---|
| Any pain | 196 |
| Grade 3 pain | 80 |
| Any redness | 91 |
| Grade 3 redness | 0 |
| Any swelling | 178 |
| Grade 3 swelling | 10 |
Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature \> 39.5°C. Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities. Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day. Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.
| subjects | Synflorix Vaccine Group |
|---|---|
| Any diarrhea | 55 |
| Grade 3 diarrhea | 5 |
| Related diarrhea | 55 |
| Any drowsiness | 156 |
| Grade 3 drowsiness | 7 |
| Related drowsiness | 153 |
| Any fever | 147 |
| Grade 3 fever | 0 |
| Related fever | 147 |
| Any irritability | 198 |
| Grade 3 irritability | 21 |
| Related irritability | 196 |
| Any loss of appetite | 113 |
| Grade 3 loss of appetite | 1 |
| Related loss of appetite | 111 |
| Any vomiting | 56 |
| Grade 3 vomiting | 7 |
| Related vomiting | 56 |
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| subjects | Synflorix Vaccine Group |
|---|---|
| Number of Subjects Reporting Any Unsolicited AEs | 174 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
| subjects | Synflorix Vaccine Group |
|---|---|
| Number of Subjects Reporting Any Serious Adverse Events (SAEs) | 15 |
Collected over Serious adverse events were assessed up to month 5. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 4 day and 31 day post vaccination period respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Synflorix Vaccine Group | — | 15/230 (6.5%) | 229/230 (99.6%) |
| Event | Synflorix Vaccine Group |
|---|---|
| BronchopneumoniaInfections and infestations | 6/230 |
| BronchiolitisInfections and infestations | 4/230 |
| DehydrationMetabolism and nutrition disorders | 2/230 |
| GastroenteritisInfections and infestations | 2/230 |
| NasopharyngitisInfections and infestations | 2/230 |
| Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders | 1/230 |
| Cerebral infarctionNervous system disorders | 1/230 |
| ConjunctivitisEye disorders | 1/230 |
| ConvulsionNervous system disorders | 1/230 |
| HerpanginaInfections and infestations | 1/230 |
| Event | Synflorix Vaccine Group |
|---|---|
| IrritabilityGeneral disorders | 198/230 |
| PainGeneral disorders | 196/230 |
| SwellingGeneral disorders | 178/230 |
| DrowsinessGeneral disorders | 156/230 |
| FeverGeneral disorders | 147/230 |
| NasopharyngitisGeneral disorders | 123/230 |
| Loss of appetiteGeneral disorders | 113/230 |
| RednessGeneral disorders | 91/230 |
| VomitingGeneral disorders | 56/230 |
| DiarrheaGeneral disorders | 55/230 |
| Age, Continuous(weeks) | Synflorix Vaccine Group |
|---|---|
| Mean | 8.2 ± 1.63 |
| Sex: Female, Male(Participants) | Synflorix Vaccine Group |
|---|---|
| Female | 123 |
| Male | 107 |
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below).
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jul 2007 to primary completion in Mar 2008, 8 months.
Results were first posted in May 2012, 4 years 1 month after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Streptococcal Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 13. This study's 8 months is below that.
Counting every sponsor, half of 29 studies reached it within 10 months; a quarter within 8 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PHiD-CV vaccine · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · RIX4414 vaccine